(+)-VINCRISTINE
Nonsquamous Nonsmall Cell Neoplasm of Lung
Intergroupe Francophone de Cancerologie ThoraciqueSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Nonsquamous Nonsmall Cell Neoplasm of Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Arcus Biosciences, Inc. | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Intergroupe Francophone de Cancerologie Thoracique | Phase 2 | BB |
Demcizumab OncoMed Pharmaceuticals, Inc. | Phase 2 | B |
Irinotecan Intergroupe Francophone de Cancerologie Thoracique | Phase 2 | B |
Nivolumab Eric Bernicker, MD | Phase 2 | CCC |
View all 20 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →